TY - BOOK ID - 5450601 TI - Combination cancer therapy : modulators and potentiators PY - 2005 SN - 9781588292001 1588292002 9781592598649 9786610359516 128035951X 1592598641 162703806X PB - Totowa, N.J. : Humana Press, DB - UniCat KW - Neoplasms KW - Drug Therapy, Combination. KW - Cancer KW - Apoptosis. KW - Apoptose KW - drug therapy. KW - Chemotherapy. KW - Treatment. KW - Chimiothérapie KW - Traitement KW - Apoptosis KW - Drug Therapy, Combination KW - Chemotherapy KW - Treatment KW - drug therapy KW - Cancer -- Chemotherapy. KW - Cancer -- Treatment. KW - Drug Therapy KW - Therapeutics KW - Diseases KW - Analytical, Diagnostic and Therapeutic Techniques and Equipment KW - Oncology KW - Medicine KW - Health & Biological Sciences KW - Cancer therapy KW - Cancer treatment KW - Therapy KW - Medicine. KW - Oncology. KW - Medicine & Public Health. KW - Tumors KW - Clinical sciences KW - Medical profession KW - Human biology KW - Life sciences KW - Medical sciences KW - Pathology KW - Physicians KW - Cell death KW - Antineoplastic agents KW - Oncology . KW - Cancer - Chemotherapy KW - Cancer - Treatment KW - Neoplasms - drug therapy UR - https://www.unicat.be/uniCat?func=search&query=sysid:5450601 AB - Early clinical trials of the new molecular-based anticancer agents have shown that many are marginal in controlling cancer, but prove to be potent modulators and potentiators of chemotherapy-induced apoptosis when used in combination with classic cytotoxic drugs or radiation. In Combination Cancer Therapy: Modulators and Potentiators, expert physician-scientists and clinicians with first-hand experience in the clinical development of targeted therapies review those combinations that hold the most promise for the future of medical oncology, detailing their optimal sequence, pharmacokinetic interactions, and interaction with downstream cellular signals. The combinations run the gamut of targeted therapies against cell surface receptors (EGF-R and HER2), the cell cycle (the CDKs), signal transduction events (PKC and NF-kB), apoptosis (bcl-2), as well as focused therapies in ovarian cancer, hematologic diseases, and breast cancer. The authors emphasize novel translational approaches that are rapidly moving from the laboratory benchtop to the patient's bedside as a new generation of cancer therapeutics. Cutting-edge and forward-looking, Combination Cancer Therapy: Modulators and Potentiators offers everyone in the fields of cancer drug development and therapy a powerful new understanding of the optimal sequencing and scheduling of new combination drug therapies necessary to maximize the effects for cancer patients today. ER -